Mirtazapine versus paroxetine in panic disorder: An open study

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 2, 2005, Pages 87-93

  Montañés Rada, Francisco ^a,c   De Lucas Taracena, M T ^a,b   Sanchez Romero S ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Mental Health Center of Tetúan   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Mirtazapine; Open study; Panic disorder; Paroxetine; SSRI

Indexed keywords

BROMAZEPAM; LORAZEPAM; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ACTIVITY; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTHESIS; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PANIC; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RECURRENT DISEASE; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 21044439347     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510018248     Document Type: Article

References (31)

1. Davidson JRT. Use of benzodiazepines in panic disorder. J Clin Psychiatry 1997;58:26-8.
2. Jefferson JW. Antidepressants in panic disorder. J Clin Psychiatry 1997;58:20-4.
3. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: A placebo-controlled trial. J Clin Psychopharmacol 1992;12: 251-61.
4. Munjack DJ, Usigli R, Zulueta A, Crocker B, Adatia N, Buckwalter JG, Baltazar P, Kurvink W, Inglove H, Kelly R. Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1998;8: 204-7.
5. Kalus O, Asnins GM, Rubinson E, Kahn R, Friedman JM, Iqbal N, Grosz D, van Praag H, Cahn W. Desipramine treatment in panic disorder. J Affect Disord 1991;21:239-44.
6. Van Vliet IM, Westenberg HG, de Boer JA. MAO inhibitors in panic disorder: cinical effects of treatment with brofaromine. Psychopharmacology 1993;112:483-9.
7. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J Clin Psychiatry 1987;48:55-9.
8. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. Int Clin Psychopharmacol 1995;10:45-9.
9. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Oshrstrom JK, Manniche PM. Paroxetine in the treatment of panic disorder: A randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-9.
10. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993;54:435-8.
11. Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999;11:81-6.
12. Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapezinski F. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001;34:1003-7.
13. Boshuisen ML, Slaap BR, Vester-Blockland ED, den Boer JA. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 2001;6:363-8.
14. Sarchiapone M, Amore M, De Risio S, Cali V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 2003;18:35-8.
15. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992;86:273-82.
16. Charney DS, Bremner JD. Noradrenergic neural substrates for anxiety and fear: Clinical association based on preclinical research. In: Bloom F, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995. p 387-97.
17. Price LH, Goddard AW, Barr L, Goodman WK. Pharmacologic challenges in anxiety disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacoly: The Fourth Generation of Progress. New York: Raven Press; 1995. p 1311-25.
18. De Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of de 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
19. Kao L, Barkin RL, Leikin J. Mirtazapine overdose: a case report. In: Medical Update for Psychiatrists, vol. 22. New York: Elsevier; 1997. p 58-9.
20. De Boer T, Ruigt GSF. The selective α2-adrenoreceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A mediated setotonergic neurotransmission. CNS Drugs 1995;4(Suppl 1):29-38.
21. Thome J, Henn FA, Duman RS. Cyclic AMP response element-binding protein ans depresion. Expert Rev Neurother 2002;2:347-54.
22. Schule C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology (Berlin) 2002;63:95-101.
23. Papp LA, Coplan JD, Martinez JM, de Jesus M, Gorman JM. Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharm 2000;20:554-6.
24. DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychopharmacol 1996;22(1):95-6.
25. Strohle A, Ehrenthal HD. J Clin Psychopharm 2002;22: 95-6.
26. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
27. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;5:893-7.
28. Stein MB, Ulm TW. Panic disorder and major depression state of two syndromes. Psychiatr Clin North Am 1988;11: 441-61.
29. Fawcett JA, Kravitz HM. Anxiety syndrome and their relationship to depressive illness. J Clin Psychiatry 1983;44:8-11.
30. Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, van Baer JA, Kasper S, Stear MK. Consensus Statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1988;59:41-54.
31. Rapaport MH, Pollack M, Wolkow R, Mardethinn J, Clary C. Is placebo response the same as drug response in panic disorder? Am J Psychiatry 2000;157:1014-6.